Genitourinary Cancers

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.

A meta-analysis found rapid progression and hyperprogression with nivolumab plus ipilimumab in renal medullary carcinoma.

A SEER analysis showed that immune checkpoint inhibitors better improved OS for younger patients vs older patients with advanced renal cell carcinoma.

Scott M. Haake, MD, PhD, discusses how RNAseq-defined clusters could guide treatment selection in metastatic ccRCC, based on data from the OPTIC trial.

Andrew W. Hahn, MD, discusses the efficacy and safety of lenvatinib plus everolimus in metastatic ccRCC after progression on PD-1–directed ICIs

Primo Nery “Lucky” Lara Jr, MD, has built a genitourinary oncology career inspired by optimism, rooted in perseverance, expanded by innovative thinking, and strengthened by a belief in the power of team science.

Neoadjuvant SABR before nephrectomy improved 12-month RFS vs surgery alone in patients with RCC with IVC tumor thrombus, with manageable safety.

Ciforadenant in combination with ipilimumab and nivolumab was safe and feasible but did not enhance activity in frontline ccRCC.

Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.

Belzutifan maintained efficacy benefits vs everolimus among patients with ccRCC after at least 2 prior VEGFR TKIs.

At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

A study combined single-cell RNA sequencing data from patients with RCC to learn about patterns of interferon signaling across cell types in tumors.

Treatment with adjuvant durvalumab plus tremelimumab resulted in a DFS benefit vs active monitoring in RCC, particularly in the higher-risk population.

Daniel P. Petrylak, MD, discusses key data in MIBC presented during the 2025 ESMO Congress and previews the 19th Annual New York GU Cancers Congress.

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

Randy F. Sweis, MD, explains future avenues for the investigation for XmAb819 in tumor types beyond renal cell carcinoma.

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

Two belzutifan-based combinations met their respective primary efficacy end points of DFS and PFS in the phase 3 LITESPARK-022 and LITESPARK-011 trials.